Early prostate cancer: prevention, treatment modalities, and quality of life issues. (Q35204620)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12932925 AND SRC:MED&resulttype=core&format=json

7 November 2019

review article

1 reference

title

Early prostate cancer: prevention, treatment modalities, and quality of life issues (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12932925 AND SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12932925 AND SRC:MED&resulttype=core&format=json

7 November 2019

author name string

J W Moul

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12932925 AND SRC:MED&resulttype=core&format=json

7 November 2019

J Anderson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12932925 AND SRC:MED&resulttype=core&format=json

7 November 2019

L H Klotz

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12932925 AND SRC:MED&resulttype=core&format=json

7 November 2019

M S Soloway

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12932925 AND SRC:MED&resulttype=core&format=json

7 November 2019

C C Schulman

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12932925 AND SRC:MED&resulttype=core&format=json

7 November 2019

language of work or name

English

0 references

publication date

1 September 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12932925 AND SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12932925 AND SRC:MED&resulttype=core&format=json

7 November 2019

volume

44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12932925 AND SRC:MED&resulttype=core&format=json

7 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12932925 AND SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

283-293

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12932925 AND SRC:MED&resulttype=core&format=json

7 November 2019

cites work

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the U.S. The American College of Surgeons Commission on Cancer and the American Cancer Society

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era.

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Improvements in pathologic staging for African-American men undergoing radical retropubic prostatectomy during the prostate specific antigen era: implications for screening a high-risk group for prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Bicalutamide as Immediate Therapy Either Alone or as Adjuvant to Standard Care of Patients with Localized or Locally Advanced Prostate Cancer: First Analysis of the Early Prostate Cancer Program

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Delaying/reducing the risk of clinical tumour progression after primary curative procedures

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Three-year results of the Finnish prostate cancer screening trial

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Randomized Screening Trial for Prostate Cancer in Finland

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Rationale for earlier and less frequent prostate cancer screening

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Prostate cancer prevention agent development: Criteria and pipeline for candidate chemoprevention agents

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Prostate Cancer and Supplementation With α-Tocopherol and β-Carotene: Incidence and Mortality in a Controlled Trial

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Nutrition and prostate cancer: evidence or suspicion?

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

PC-SPES: current evidence and remaining questions

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Complementary and alternative therapies for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

The future of prostate cancer prevention

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

COX-2 inhibition and prevention of cancer

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Additional treatments and reimbursement rates associated with prostate cancer treatment for patients undergoing radical prostatectomy, interstitial brachytherapy, and external beam radiotherapy

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

The bicalutamide Early Prostate Cancer Program. Demography

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Combination of long-acting microcapsules of the D-tryptophan-6 analog of luteinizing hormone-releasing hormone with chemotherapy: investigation in the rat prostate cancer model

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Definitions of biochemical failure in prostate cancer following radiation therapy.

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

The definition of biochemical failure in patients treated with definitive radiotherapy

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Prostate-specific antigen after radiation therapy. Prognosis by pretreatment level and post-treatment nadir

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

A standard definition of disease freedom is needed for prostate cancer: undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Apples and oranges: building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Does the service at a large oncologic out-patient clinic satisfy the patients' perceived need?

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Waning sexual function--the most important disease-specific distress for patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Sex or survival: trade-offs between quality and quantity of life

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Patient preferences: survival vs quality-of-life considerations

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Urinary symptoms, potency, and quality of life in patients with localized prostate cancer followed up with deferred treatment

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

The development of erectile dysfunction in men treated for prostate cancer

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Multicenter patient self-reporting questionnaire on impotence, incontinence and stricture after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Early quality of life in patients with localized prostate carcinoma: an examination of treatment-related, demographic, and psychosocial factors

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Quality of life changes during conformal radiation therapy for prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

The Golombok-Rust Inventory of Sexual Satisfaction (GRISS)

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Quality of life issues relating to endocrine treatment options.

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument.

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy.

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Quality of life in T1-3N0 prostate cancer patients treated with radiation therapy with minimum 10-year follow-up

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Measurement of health-related quality of life in men with prostate cancer: the CaPSURE database

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Measurement of quality of life in localized prostatic cancer patients treated with radiotherapy. Development of a prostate cancer-specific module supplementing the EORTC QLQ-C30.

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Quality of life in patients with prostatic cancer: results from a Swedish population study

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy.

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Gynecomastia in patients with prostate cancer: a review of treatment options

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Gynaecomastia: aetiology and treatment options

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group

1 reference

https://api.crossref.org/works/10.1016/S0302-2838(03)00296-3

7 January 2021

10.1016/S0302-2838(03)00296-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12932925 AND SRC:MED&resulttype=core&format=json

release_c7djtgabtrawxdgzb73ztaflx4

7 November 2019

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/c7djtgabtrawxdgzb73ztaflx4

24 November 2022

mapped directly with Wikidata item

1 reference